跳至主要内容
临床试验/CTRI/2012/11/003145
CTRI/2012/11/003145招募中2 期

A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis

ovaBay Pharmaceutical Inc0 个研究点目标入组 440 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
440

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Subjects must be >= 18 years of age and <= 65 years of age
  • 2. At least 1 eye (and in that same eye) must have onset and development of ocular symptoms and/or signs of conjunctivitis <= 3 days prior to enrollment (Day 1)
  • 3. Females who are not pregnant and are not lactating.
  • 4. Other inclusion criteria per protocol.

排除标准

  • 1.Presence of subepithelial infiltrates (SEIs) at the Day 1 visit in either eye.
  • 2.Suspected bacterial, fungal, herpes, Chlamydia or Acanthamoeba co-infection, based on clinical observation.
  • 3.Subjects with ocular condition(s) that may interfere with the conduct of the study as outlined in the protocol.
  • 4.Other exclusion criteria per protocol.

研究者

发起方
ovaBay Pharmaceutical Inc

相似试验

A Clinical Trial to study the effects of NVC-422... | 临床试验